

S2 Table. Comparison of stage IIIB and IIIC NSCLC patients' baseline characteristics according to treatment modality

Characteristic	Total	CCRT group	CTx group	RT group	p-value
No. of patients	570	201 (35.3)	307 (53.9)	62 (10.9)	
Age (yr)	69 (61-75)	65 (58-71)	71 (64-76)	77 (71-80)	< 0.001
Male sex	463 (81.2)	167 (83.1)	244 (79.5)	52 (83.9)	0.508
Ever-smoker (n=565)	436 (77.2)	157 (78.5)	227 (74.9)	52 (83.9)	0.265
BMI (kg/m ²)	23.8±20.0	23.0±3.6	24.7±27.2	22.3±3.5	0.538
Symptoms					
Asymptomatic	60 (10.5)	19 (9.5)	32 (10.4)	9 (14.5)	0.523
Cough	254 (44.6)	89 (44.3)	141 (45.9)	24 (38.7)	0.577
Sputum	150 (26.3)	46 (22.9)	91 (29.6)	13 (21.0)	0.143
Dyspnea	104 (18.2)	23 (11.4)	65 (21.2)	16 (25.8)	0.006
Hoarseness	21 (3.7)	8 (4.0)	11 (3.6)	2 (3.2)	0.954
Hemoptysis	72 (12.6)	26 (12.9)	39 (12.7)	7 (11.3)	0.942
Weight loss	48 (8.4)	15 (7.5)	28 (9.1)	5 (8.1)	0.801
Pain	100 (17.5)	41 (20.4)	48 (15.6)	11 (17.7)	0.385
Performance status (n=454)					< 0.001
0-1	403 (88.8)	168 (93.8)	205 (89.5)	31 (66.0)	
2-4	51 (11.2)	11 (6.2)	24 (10.5)	16 (34.0)	

Values are presented as median (interquartile range), number (%), or mean±standard deviation. BMI, body mass index; CCRT, concurrent chemotherapy and radiation therapy; CTx, chemotherapy; RT, radiation therapy; NSCLC, non-small cell lung cancer.